CY1113205T1 - Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου - Google Patents

Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου

Info

Publication number
CY1113205T1
CY1113205T1 CY20121100954T CY121100954T CY1113205T1 CY 1113205 T1 CY1113205 T1 CY 1113205T1 CY 20121100954 T CY20121100954 T CY 20121100954T CY 121100954 T CY121100954 T CY 121100954T CY 1113205 T1 CY1113205 T1 CY 1113205T1
Authority
CY
Cyprus
Prior art keywords
macrofag
activation
regulation
macrophage activation
compounds
Prior art date
Application number
CY20121100954T
Other languages
English (en)
Inventor
Celine Morissette
Francine Gervais
Original Assignee
Bhi Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhi Limited Partnership filed Critical Bhi Limited Partnership
Publication of CY1113205T1 publication Critical patent/CY1113205T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Ανιονικές ενώσεις, που συμπεριλαμβάνουν σουλφονικά είναι ικανές αναστολής διεγειρόμενης από Αβ ενεργοποίησης μακροφάγου (ή ενεργοποίηση μακροφάγου που διεγείρεται από άλλες αμυλοειδογονικές πρωτεΐνες ή πεπτίδια). Τέτοιες ενώσεις μπορεί να αναστέλλουν τη φλεγμονώδη διεργασία, π.χ., εγκέφαλο ενός υποκειμένου που υποφέρει από μια ασθένεια που χαρακτηρίζεται από απόθεση Αβ, όπως ασθένεια Alzheimer.
CY20121100954T 1998-02-11 2012-10-16 Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου CY1113205T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7429598P 1998-02-11 1998-02-11
US24839699A 1999-02-10 1999-02-10
EP99903869A EP1054664B1 (en) 1998-02-11 1999-02-11 Method for modulating macrophage activation

Publications (1)

Publication Number Publication Date
CY1113205T1 true CY1113205T1 (el) 2016-04-13

Family

ID=26755484

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100954T CY1113205T1 (el) 1998-02-11 2012-10-16 Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου

Country Status (13)

Country Link
EP (1) EP1054664B1 (el)
JP (1) JP4574845B2 (el)
AU (1) AU2437899A (el)
CA (2) CA2632106A1 (el)
CY (1) CY1113205T1 (el)
DK (1) DK1054664T3 (el)
ES (1) ES2392391T3 (el)
HK (1) HK1032915A1 (el)
IL (1) IL137751A0 (el)
MX (2) MX2008014823A (el)
NZ (2) NZ568553A (el)
PT (1) PT1054664E (el)
WO (1) WO1999040909A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
AU3726299A (en) * 1998-05-15 1999-12-06 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
DE60042896D1 (de) * 1999-04-28 2009-10-15 Bellus Health Int Ltd Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
EP1251837A2 (en) * 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
EP1646659B1 (en) * 2003-06-23 2014-05-14 Kiacta Sàrl Method for the preparation of 1,3-propane disulfonic acid compounds
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
CN102898519B (zh) 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
EP1968561B8 (en) 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JP2012517822A (ja) * 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
SG10202100421XA (en) * 2009-09-17 2021-02-25 Bespoke Bioscience Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2016163886A2 (en) * 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN109381452A (zh) * 2017-08-11 2019-02-26 江西青峰药业有限公司 乙基硫酸类化合物的应用及其制备方法
CN109381453A (zh) * 2017-08-14 2019-02-26 江西青峰药业有限公司 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用
CN109394746A (zh) * 2017-08-15 2019-03-01 江西青峰药业有限公司 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
EP1614416A3 (en) * 1993-03-29 2009-07-01 BELLUS Health (International) Limited Method for treating amyloidosis
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
IL134619A0 (en) * 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis

Also Published As

Publication number Publication date
CA2320224A1 (en) 1999-08-19
MX2008014823A (es) 2009-03-06
JP2002502871A (ja) 2002-01-29
CA2632106A1 (en) 1999-08-19
PT1054664E (pt) 2012-11-02
NZ568553A (en) 2010-02-26
MXPA00007815A (es) 2002-04-24
ES2392391T3 (es) 2012-12-10
AU2437899A (en) 1999-08-30
WO1999040909A1 (en) 1999-08-19
EP1054664B1 (en) 2012-08-08
CA2320224C (en) 2008-08-12
EP1054664A1 (en) 2000-11-29
NZ550199A (en) 2008-07-31
JP4574845B2 (ja) 2010-11-04
DK1054664T3 (da) 2012-11-05
HK1032915A1 (en) 2001-08-10
IL137751A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
CY1113205T1 (el) Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου
NO994689D0 (no) Fremgangsmaate til aa diagnostisere psykiatriske lidelser
CY1105517T1 (el) 2-oxo-1-pyrrolidine παραγωγο και οι φαρμακευτικες του χρησεις
DK1054860T3 (da) Proces for syntesen af 1,3-dioler
MY126559A (en) Fungicidal 2-methoxybenzophenones
MX219633B (es) Procedimiento autotermico para la produccion de olefinas.
ES2172864T3 (es) 2-metoxibenzofenonas fungicidas.
BR9609744A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
ITMI951445A0 (it) Procedimento per la produzione di carbammati aromatici
IT1283232B1 (it) Procedimento per la sintesi di 2-buten-1, 4-diesteri
YU61103A (sh) Postupci za produkciju supstituisanih 2-(2-piridilmetil) sulfinil-1h-benzimidazola
TR200103551T2 (tr) Amiloid protein birikimini önleme ve amiloid tortularını görüntüleme metodu
BR9915868A (pt) Processo para a decomposição de tramadol
IT1298096B1 (it) Procedimento per la produzione di gamma-butirrolattone
ZA99939B (en) Process for the preparation of 2-aryl-5-(perfluoroalkyl) pyrrole compounds from N-(perfluoroalkylmethyl) arylimidoyl chloride compounds.
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
NO971972L (no) Hydrofon, samt fremgangsmåte for fremstilling av denne
BR9712773A (pt) Processo para a sìntese de benzotiofenos
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
IT1261221B (it) Procedimento per inibire la formazione di composti di decomposizione dal riscaldamento di 1,1-dicloro-1-fluoroetano.
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
NO991675D0 (no) FremgangsmÕte for alkylering av hindrede sulfonamider
IT1305296B1 (it) Procedimento per la produzione di dolomite sintetica.
IT1303824B1 (it) Procedimento per la produzione di caprolattame di elevata purezza.
EE200000597A (et) R-(+)-6-karboksamido-3-N-metüülamino-1,2,3,4-tetrahüdrokarbasooli tootmise meetod